Announcement no. 7/2008
To the OMX Nordic Exchange Copenhagen Copenhagen,
April 21, 2008
Voting Proxies issued to the Board of Directors
In accordance with Section 29 of the Danish Securities Trading Act, cf. Sections
4, no. 8 and 5, subsection 3 of Executive Order No. 1225 of 22 October 2007,
Curalogic A/S hereby announces that the Board of Directors has received proxies
from a number of shareholders authorising the Board of Directors of Curalogic
A/S to vote on their behalf at the Annual General Meeting on April 21, 2008. On
April 16, 2008 the Board of Directors of Curalogic A/S received voting proxies
resulting in the Board of Directors being authorised to vote on shares
corresponding to more than 15 per cent of Curalogic A/S' total aggregate voting
rights. On April 17, 2008 one of the company's larger shareholders chose to
withdraw their general voting proxy due to practical considerations and replaced
it with a voting proxy with specific instructions. As a result the Board of
Directors of Curalogic A/S is hereafter authorised to vote on shares
corresponding to more than 10 per cent of Curalogic A/S' total aggregate voting
rights. As of this date the Board of Directors thus controls voting rights which
in aggregate amounts to 13.3 per cent of Curalogic A/S' share capital and voting
rights.
On April 21, 2008 after the Annual General Meeting, the authorisation of the
Board of Directors to vote according to the voting proxies
will terminate. Standard notification form according to Executive Order No. 1225
of 22 October 2007 is attached to this announcement.
Yours faithfully,
Curalogic A/S
For additional information, please contact:
Peter Moldt, President and CEO, Phone +45 99 99 24 01
Helle Busck Fensvig, EVP and CFO, Phone +45 99 99 24 03
About Curalogic
Curalogic is a Danish biopharmaceutical company listed on the OMX Nordic
Exchange Copenhagen (CUR.CO) as a SmallCap+ company. Curalogic has ample cash
resources and has demonstrated its ability to conduct complex clinical studies
with a small group of development experts. Curalogic has initiated a search
process to identify development projects offering an attractive risk profile.
Curalogic expects to conclude an agreement during 2008 that will secure future
clinical development projects for the Company.
This announcement contains forward-looking statements regarding the Company's
future financial development and performance and other statements which are not
historical facts. Such statements are made on the basis of assumptions and
expectations which, to the best of the Company's knowledge and belief, are
reasonable, at this time, but may prove to be erroneous in the future.
